A national survey of physicians found strong support for key policies that could help prevent opioid misuse, but report encountering barriers.
A national survey of physicians found strong support for improving prescription drug monitoring programs (PDMPs) as one way to help prevent opioid misuse.
Having lost 30,000 lives due to abuse of prescription opioids and heroin, the American Medical Association (AMA) surveyed physicians nationwide for their opinion on the opioid epidemic and how the issue can be resolved.
Other policies to end the epidemic that had strong support from respondents included increasing physician education and removing obstacles to effective care. Of the physicians surveyed, 87% agree that PDMPs offer insights into the patient’s medical history, 68% have taken continuing medical education (CME) on safe opioid prescription, 55% have taken CME on pain management with opioid alternatives, and 80% said that naloxone should be readily available to patients.
The survey also showed that many physicians actively seek more education and that 25% said that CME was not easily accessible or did not address their needs.
“This new survey helps underscore that medical societies must be leaders in providing the best resources possible to our colleagues in every state and for every specialty, both for appropriate opioid prescribing and in urging physicians to register for and use PDMPs,” AMA President Steven J. Stack, MD, said in a statement.
AMA President Steven J. Stack, MD, issued a call to action that included 5 recommendations for combatting the opioid epidemic. First, physicians should consider registering and using their states’ PDMPs. Second, physicians should seek to enhance their education and training in safe prescribing drugs, especially knowing when opioids are appropriate to the patient’s situation. Third, they should co-prescribe naloxone to patients who may be at a risk for overdose. Fourth, they should receive medication-assisted treatment training in order to provide for those with substance use disorders. Fifth, they should treat all patients with compassion rather than judgment, and not stigmatize those who do have substance use disorders.
“If a physician is considering prescribing an opioid—whether for acute or chronic pain—we strongly encourage physicians to ensure that they are current in their knowledge and training as to when an opioid is appropriate—and when it is not,” said Dr Stack.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More